LADENBURG THALMANN FINANCIAL SERVICES INC. - BIOCRYST PHARMACEUTICALS INC ownership

BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 121 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2017. The put-call ratio across all filers is 0.18 and the average weighting 0.4%.

Quarter-by-quarter ownership
LADENBURG THALMANN FINANCIAL SERVICES INC. ownership history of BIOCRYST PHARMACEUTICALS INC
ValueSharesWeighting
Q4 2019$88,000
+17.3%
25,673
-1.9%
0.00%0.0%
Q3 2019$75,000
+2400.0%
26,173
+4101.1%
0.00%
Q2 2019$3,000
-25.0%
623
+27.4%
0.00%
Q1 2019$4,000
+33.3%
489
+25.7%
0.00%
Q4 2018$3,000
-25.0%
389
-20.4%
0.00%
Q3 2018$4,000
+100.0%
489
+25.7%
0.00%
Q2 2018$2,0000.0%3890.0%0.00%
Q1 2018$2,0000.0%3890.0%0.00%
Q4 2017$2,0000.0%3890.0%0.00%
Q3 2017$2,0000.0%3890.0%0.00%
Q2 2017$2,000
-33.3%
3890.0%0.00%
Q1 2017$3,000
+50.0%
3890.0%0.00%
Q4 2016$2,0000.0%3890.0%0.00%
Q3 2016$2,000
-96.6%
389
-98.1%
0.00%
-100.0%
Q2 2016$58,000
+100.0%
20,389
+96.3%
0.00%0.0%
Q1 2016$29,000
+625.0%
10,389
+2570.7%
0.00%
Q4 2015$4,0000.0%3890.0%0.00%
Q3 2015$4,000
-96.4%
389
-94.7%
0.00%
-100.0%
Q2 2015$110,000
+214.3%
7,389
+90.0%
0.00%
+100.0%
Q1 2015$35,000
-18.6%
3,889
+11.1%
0.00%0.0%
Q4 2014$43,000
+48.3%
3,500
+16.7%
0.00%0.0%
Q3 2014$29,000
-23.7%
3,0000.0%0.00%0.0%
Q2 2014$38,000
+375.0%
3,000
+200.0%
0.00%
Q4 2013$8,000
+14.3%
1,0000.0%0.00%
Q3 2013$7,000
-83.7%
1,000
-96.4%
0.00%
-100.0%
Q2 2013$43,00028,0000.00%
Other shareholders
BIOCRYST PHARMACEUTICALS INC shareholders Q1 2017
NameSharesValueWeighting ↓
VHCP Management, LLC 1,744,356$18,455,0009.59%
RA Capital Management 4,347,456$45,996,0003.30%
Cormorant Asset Management, LP 1,168,000$12,357,0002.84%
Baker Brothers Advisors 5,867,031$62,073,0000.79%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 907,920$9,606,0000.39%
QVT Financial LP 525,734$5,562,0000.32%
EAM Investors, LLC 114,548$1,212,0000.22%
FRANKLIN STREET ADVISORS INC /NC 93,000$984,0000.20%
THB ASSET MANAGEMENT 301,529$3,190,0000.19%
TPG Group Holdings (SBS) Advisors, Inc. 1,162,269$12,297,0000.13%
View complete list of BIOCRYST PHARMACEUTICALS INC shareholders